Autolus Therapeutics Presents Additional Data Analysis Of Pivotal Phase 2 Felix Study Of obe-cel For Adult r/r B-all In An Oral Presentation At ASCO
Portfolio Pulse from Benzinga Newsdesk
Autolus Therapeutics presented additional data from its Phase 2 FELIX study of obe-cel for adult r/r B-ALL at the ASCO Annual Meeting. The data showed durable responses in the majority of patients, with 40% in ongoing remission without further intervention. The company will discuss the data in a webcast on June 1, 2024.
May 31, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Autolus Therapeutics presented promising data from its Phase 2 FELIX study of obe-cel, showing durable responses and 40% of patients in ongoing remission without further intervention. This could positively impact the stock price in the short term.
The positive data from the Phase 2 FELIX study, showing durable responses and a significant percentage of patients in remission, is likely to boost investor confidence and positively impact the stock price of Autolus Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100